Antibiotics

US hospitals have made significant reductions in the incidence of hospital-acquired infections (HAIs) over the past decade, a new report from the Centers for Disease Control and Prevention (CDC) has revealed.

The Centers for Disease Control and Prevention believes far too many Americans are exposed to "dangerous, drug-resistant bacteria" in hospitals and other healthcare settings.

Jason C. Gallagher, PharmD explains the most important thing healthcare practitioners should keep in mind about antimicrobial stewardship.

Researchers have discovered a new class of chemical compounds that work to inhibit biofilm formation, thereby identifying a potential new therapeutic target for the treatment of infections caused by Acinetobacter baumannii.

A recent article endeavors to draw new-- and perhaps increased-- attention to the issue of neurologic side effects associated with antibiotic use in hospitalized patients.

Jason C. Gallagher, PharmD explains what healthcare providers can do to help address antimicrobial resistance.

The antibacterial drug Avycaz (ceftazidime-avibactam) was given priority review by the Food and Drug Administration (FDA) since new safety data has been discovered.

A new trial conducted in England has discovered a cost-effective way to reduce the overprescribing of antibiotics by general practitioners (GPs).

Dr. Jason C. Gallagher, PharmD, Clinical Professor at the Temple University School of Pharmacy describes the difference between antimicrobial and antibiotic resistance.

Jason C. Gallagher, PharmD, explains what healthcare providers can do to help address antibiotic resistance.

After swabbing 20 beards, more than 100 bacteria growths were identified.

There appears to be a positive correlation between higher antibiotic use and the development of type 2 diabetes, according to a study published in The Journal of Clinical Endocrinology & Metabolism.